ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,3,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
2,1,Salivary gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
3,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
4,1,Skin striae,Skin hypoplasias and atrophies,Cornification and dystrophic skin disorders,Skin,N
5,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
6,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
7,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
7,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
7,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
8,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
9,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
10,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
10,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
10,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
10,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
12,1,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
12,2,Hunger,Feelings and sensations NEC,General system disorders NEC,Genrl,N
12,3,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
12,4,Sensory disturbance,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
12,5,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
13,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
13,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
13,3,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
13,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
14,1,Application site inflammation,Application site reactions,Administration site reactions,Genrl,N
14,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
14,3,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
15,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
15,2,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
16,1,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
16,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
17,1,Administration site pain,Administration site reactions NEC,Administration site reactions,Genrl,N
17,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
17,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
18,1,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
18,2,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
19,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
